FDA Purple Book · Reference family
cosibelimab-ipdl (Unloxcyt)
cosibelimab-ipdl is an FDA-licensed reference biologic from Checkpoint Therapeutics, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2024
Reference approved
Reference product
351(a)BLA 761297
Unloxcyt cosibelimab-ipdl
Checkpoint Therapeutics, Inc.
- Approved
- Dec 13, 2024
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for cosibelimab-ipdl, in chronological order.
Reference approval
Approval date of the reference cosibelimab-ipdl product.
1 yr 6 mo ago
Frequently asked questions
Are there biosimilars approved for cosibelimab-ipdl (Unloxcyt)?
No 351(k) biosimilars or interchangeable biosimilars referencing cosibelimab-ipdl are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.